Early viral kinetics on treatment with pegylated interferon‐α‐2a in chronic hepatitis C virus genotype 1 infection *

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Viral Hepatitis

• Publication date

  2003-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2893.2003.00396.xPMID 12558910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa‐2b plus ribavirin

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.

  2001cited by this paper
• Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.

  2001cited by this paper
• Hepatitis C virus resistance to antiviral therapy

  2000cited by this paper
• Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy

  2000cited by this paper
• PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Mutations in the E2‐PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment

  2000cited by this paper
• The NS5a gene of hepatitis C virus in patients treated with interferon‐α

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Combination therapy with lamivudine and famciclovir for chronic hepatitis B–infected Chinese patients: A viral dynamics study

  2000cited by this paper
• Association of amino acid sequence in the PKR‐eIF2 phosphorylation homology domain and response to interferon therapy

  2000cited by this paper
• Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon.

  2000cited by this paper
• EASL International Consensus Conference on Hepatitis C

  1999cited by this paper
• Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

  1999cited by this paper
• EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

  1999cited by this paper
• Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C

  1997cited by this paper
• Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

  1997cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Treatment of chronic hepatitis C with recombinant interferon alfa.

  1991cited by this paper
• Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

  1989cited by this paper

• Hepatitis C virus resistance to interferon therapy: an alarming situation

  2014cites this paper
• Early and Sustained Virological Response in Non-Responders with Chronic Hepatitis C

  2012cites this paper
• Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

  2011cites this paper
• Hepatitis C treatment response kinetics and impact of baseline predictors

  2011cites this paper
• Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon‐alpha‐2b‐ribavirin combination therapy

  2010cites this paper
• An early viral response to standard interferon‐alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1

  2010cites this paper
• Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load

  2009cites this paper
• Plasma HCV‐RNA decline in the first 48 h identifies hepatitis C virus mono‐infected but not HCV/HIV‐coinfected patients with an undetectable HCV viral load at week 4 of peginterferon‐alfa‐2a/ribavirin therapy

  2009cites this paper
• A liver slice culture‐based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C

  2009cites this paper
• Predicting the response to 48‐week combination therapy with peginterferon α‐2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients

  2009cites this paper
• Chronic Hepatitis C Patients Pegylated Interferon and Ribavirin in Sustained Virological Response to TaqMan HCV Assays for Prediction of and Roche Cobas AmpliPrep / Cobas Abbott RealTime Hepatitis C Virus ( HCV )

  2009cites this paper
• Very Early Viral Kinetics on Interferon Treatment in Chronic Hepatitis C virus Genotype 4 Infection

  2008cites this paper
• Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy

  2008cites this paper
• Towards optimal treatment for chronic hepatitis C infection

  2008cites this paper
• Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co‐infection

  2008cites this paper
• Treatment predictors of a sustained virologic response in hepatitis B and C.

  2008cites this paper
• IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV–HCV Coinfection

  2008cites this paper
• Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients

  2008cites this paper
• Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.

  2008cites this paper
• Managing chronic hepatitis C in the difficult-to-treat patient

  2007cites this paper
• Comparison of the Bayer VERSANT HCV RNA 3.0 and the Roche COBAS Amplicor HCV Monitor, Version 2.0, assays in HCV genotype 4 infection

  2007cites this paper
• First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C.

  2006cites this paper
• Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.

  2006cites this paper
• Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: Implications for clinical management of patients with chronic hepatitis C virus infection

  2006cites this paper
• Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV – focus on pegylated interferon-alpha

  2006cites this paper
• Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.

  2006cites this paper
• Review article: predicting response in hepatitis C virus therapy

  2006cites this paper
• Twenty‐four hour kinetics of hepatitis C virus and antiviral effect of alpha‐interferon

  2006influential citation
• The kinetics of hepatitis C virus

  2006cites this paper
• Pegylation of IFN-alpha and antiviral activity.

  2006cites this paper
• Viral kinetics in the treatment of chronic hepatitis C

  2006cites this paper
• Pegylation of IFN-α and Antiviral Activity

  2006cites this paper
• Des puces à protéines/peptides pour des applications en recherche fondamentale et clinique

  2006cites this paper
• Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α‐2b and ribavirin

  2005cites this paper
• Ribavirin mutagenesis: Hidden clues in mathematical models

  2005cites this paper
• Patient Education and Treatment Strategies Implemented at a Pharmacist‐Managed Hepatitis C Virus Clinic

  2005cites this paper
• Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon‐alpha 2a and ribavirin according to virological response

  2005cites this paper
• Estudo da cinética viral do vírus da hepatite C em pacientes co-infectados com o HIV

  2005cites this paper
• Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon-α2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy

  2005cites this paper
• Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.

  2005cites this paper
• Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response

  2005cites this paper
• Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection

  2005cites this paper
• Predictors of response to therapy for chronic hepatitis C.

  2004cites this paper
• Hepatitis C Genotyping by Denaturing High-Performance Liquid Chromatography

  2004cites this paper
• [Hepatitis C-virus --virus kinetics and resistance mechanisms].

  2004cites this paper
• Predictors of Response to Therapy for Chronic Hepatitis C

  2004cites this paper
• Hepatitis C viral kinetics

  2004cites this paper
• Hepatitis-C-Virus - Viruskinetik und Resistenzmechanismen

  2004cites this paper
• Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.

  2004cites this paper
• HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.

  2004cites this paper
• Update on viral kinetics and hcv antiviral therapy

  2004cites this paper
• Entrée de la protéine de la capside du virus de l'hépatite C dans les cellules humaines

  2004cites this paper
• Twice‐weekly administration of peginterferon‐α‐2b improves viral kinetics in patients with chronic hepatitis C genotype 1

  2003cites this paper
• Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'?

  2003cites this paper
• PEGINTERFERON ALFA‐2A (40KD) (PEGASYS®) FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

  2003cites this paper
• Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.

  2003cites this paper
• Hepatitis C viral dynamics: basic concept and clinical significance.

  2002cites this paper